Psoriasis
Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis
By Dong C, Wang Y, Sun J and 9 others.
Abstract
Background
Psoriasis is a prevalent immune-mediated inflammatory skin disease. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, provides a novel therapeutic option, but real-world data on its short-term efficacy, safety, and predictors of response among Chinese patients remain limited.
Objective
To evaluate the 12-week efficacy, safety, and predictors of response to deucravacitinib in Chinese patients with moderate-to-severe plaque psoriasis in a real-world setting.
Methods
This prospective, single-center cohort study enrolled 120 adult patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index ≥10, body surface area ≥10%, or Dermatology Life Quality Index ≥10) at a tertiary hospital in Shanghai, China. All patients received oral deucravacitinib 6 mg once daily for 12 weeks.